Valerio Therapeutics announces acquisition of Emglev Therapeutics
Valerio Therapeutics acquires Emglev Therapeutics to enhance drug development capabilities, leveraging Emglev's synthetic single-domain antibody (sdAb) libraries for innovative therapeutics in multiple areas, including autoimmune diseases, inflammatory disorders, and cancer.
© Copyright 2024. All Rights Reserved by MedPath